With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.

How has the relationship between Big Pharma and biotech evolved? And where do CROs fit into the mix? Dearth of VC funding forcing difficult biotech decisions The realities of the global economy ...